ME02324B - Alfa-aminoamidni derivati djelotvorni u tretmanu sindroma nemirnih nogu - Google Patents
Alfa-aminoamidni derivati djelotvorni u tretmanu sindroma nemirnih noguInfo
- Publication number
- ME02324B ME02324B MEP-2016-18A MEP1816A ME02324B ME 02324 B ME02324 B ME 02324B ME P1816 A MEP1816 A ME P1816A ME 02324 B ME02324 B ME 02324B
- Authority
- ME
- Montenegro
- Prior art keywords
- benzylamino
- propanamide
- fluorobenzyloxy
- methyl
- acetamide
- Prior art date
Links
- 208000005793 Restless legs syndrome Diseases 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 5
- -1 2-[4-(3-Fluorobenzyloxy)-benzyloxy]-N-methyl-propanamide Chemical compound 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 claims 2
- AHMWTDOZNQOCAI-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC=C(F)C=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1F AHMWTDOZNQOCAI-UHFFFAOYSA-N 0.000 claims 1
- SUAPKJRANCSCBZ-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC=C(F)C=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 SUAPKJRANCSCBZ-UHFFFAOYSA-N 0.000 claims 1
- UZUNVRHFYYUUJH-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1F UZUNVRHFYYUUJH-UHFFFAOYSA-N 0.000 claims 1
- RBPLIQLNWOKJFW-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 RBPLIQLNWOKJFW-UHFFFAOYSA-N 0.000 claims 1
- FVPIWKJMLINOHB-UHFFFAOYSA-N 2-[(4-benzylsulfanylphenyl)methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1SCC1=CC=CC=C1 FVPIWKJMLINOHB-UHFFFAOYSA-N 0.000 claims 1
- IEHDKRBHKAGVKZ-UHFFFAOYSA-N 2-[(4-phenylmethoxyphenyl)methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC=C1 IEHDKRBHKAGVKZ-UHFFFAOYSA-N 0.000 claims 1
- FAMQOOVSHKPIHZ-UHFFFAOYSA-N 2-[(4-thiophen-2-yloxyphenyl)methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OC1=CC=CS1 FAMQOOVSHKPIHZ-UHFFFAOYSA-N 0.000 claims 1
- BMPOJUVVLQGTSW-UHFFFAOYSA-N 2-[2-[4-[(3-chlorophenyl)methoxy]phenyl]ethylamino]propanamide Chemical compound C1=CC(CCNC(C)C(N)=O)=CC=C1OCC1=CC=CC(Cl)=C1 BMPOJUVVLQGTSW-UHFFFAOYSA-N 0.000 claims 1
- KYGCCDPEFAOIFA-UHFFFAOYSA-N 2-[[4-(3-phenylpropoxy)phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCCCC1=CC=CC=C1 KYGCCDPEFAOIFA-UHFFFAOYSA-N 0.000 claims 1
- DWHVPAYXTBJTSK-UHFFFAOYSA-N 2-[[4-(4-phenylbutoxy)phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCCCCC1=CC=CC=C1 DWHVPAYXTBJTSK-UHFFFAOYSA-N 0.000 claims 1
- OMSNFOXNGYYQRI-UHFFFAOYSA-N 2-[[4-(5-phenylpentoxy)phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCCCCCC1=CC=CC=C1 OMSNFOXNGYYQRI-UHFFFAOYSA-N 0.000 claims 1
- QWRXERHYJYREES-UHFFFAOYSA-N 2-[[4-[(2-chlorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC=C1Cl QWRXERHYJYREES-UHFFFAOYSA-N 0.000 claims 1
- JYXHMCQBDXKJFB-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methyl-methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(N)=O)N(C)CC(C=C1)=CC=C1OCC1=CC=CC=C1F JYXHMCQBDXKJFB-UHFFFAOYSA-N 0.000 claims 1
- OOTDSHVAUGIWQG-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-1-pyrrolidin-1-ylpropan-1-one Chemical compound C1CCCN1C(=O)C(C)NCC(C=C1)=CC=C1OCC1=CC=CC=C1F OOTDSHVAUGIWQG-UHFFFAOYSA-N 0.000 claims 1
- ARKJBLYSUDCWBM-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-2-methylpropanamide Chemical compound C1=CC(CNC(C)(C)C(N)=O)=CC=C1OCC1=CC=CC=C1F ARKJBLYSUDCWBM-UHFFFAOYSA-N 0.000 claims 1
- KWMDBCXQGPZBCB-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1F KWMDBCXQGPZBCB-UHFFFAOYSA-N 0.000 claims 1
- ALWXTQNAGVDEMX-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC=C1F ALWXTQNAGVDEMX-UHFFFAOYSA-N 0.000 claims 1
- HYRAJPATCBQKCF-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide Chemical compound C1=CC(CNC(CO)C(=O)N)=CC=C1OCC1=CC=CC=C1F HYRAJPATCBQKCF-UHFFFAOYSA-N 0.000 claims 1
- WGXNRJBCPJAUOL-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-n-methylpropanamide Chemical compound C1=CC(CNC(C)C(=O)NC)=CC=C1OCC1=CC=CC=C1F WGXNRJBCPJAUOL-UHFFFAOYSA-N 0.000 claims 1
- CXWAISQTEMSTKD-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methylsulfanyl]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1SCC1=CC=CC=C1F CXWAISQTEMSTKD-UHFFFAOYSA-N 0.000 claims 1
- OBIIMYCBFFXWQB-UHFFFAOYSA-N 2-[[4-[(2-methoxyphenyl)methoxy]phenyl]methylamino]propanamide Chemical compound COC1=CC=CC=C1COC1=CC=C(CNC(C)C(N)=O)C=C1 OBIIMYCBFFXWQB-UHFFFAOYSA-N 0.000 claims 1
- MODFUWXCNUBNKW-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-2-(3-fluorophenyl)acetamide Chemical compound C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 MODFUWXCNUBNKW-UHFFFAOYSA-N 0.000 claims 1
- UGAZPYAMTAVKDF-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 UGAZPYAMTAVKDF-UHFFFAOYSA-N 0.000 claims 1
- JFADNUHMEURSIM-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC(Cl)=C1 JFADNUHMEURSIM-UHFFFAOYSA-N 0.000 claims 1
- XWCJJIVVFMWOQA-UHFFFAOYSA-N 2-[[4-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n,2-dimethylpropanamide Chemical compound C1=CC(CNC(C)(CO)C(=O)NC)=CC=C1OCC1=CC=CC(C#N)=C1 XWCJJIVVFMWOQA-UHFFFAOYSA-N 0.000 claims 1
- QNGQPQCXSOZZQG-UHFFFAOYSA-N 2-[[4-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC(C#N)=C1 QNGQPQCXSOZZQG-UHFFFAOYSA-N 0.000 claims 1
- BBMKDZGTJLFKTA-UHFFFAOYSA-N 2-[[4-[(3-cyanophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC(C#N)=C1 BBMKDZGTJLFKTA-UHFFFAOYSA-N 0.000 claims 1
- CYZUAXYGTDLCAW-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl-methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(N)=O)N(C)CC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 CYZUAXYGTDLCAW-UHFFFAOYSA-N 0.000 claims 1
- MQLXKWISZJYEOW-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-1-pyrrolidin-1-ylpropan-1-one Chemical compound C1CCCN1C(=O)C(C)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 MQLXKWISZJYEOW-UHFFFAOYSA-N 0.000 claims 1
- JEARPZLCKWXTFT-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-2-methylpropanamide Chemical compound C1=CC(CNC(C)(C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 JEARPZLCKWXTFT-UHFFFAOYSA-N 0.000 claims 1
- HAQWBSZODRWECB-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC(F)=C1 HAQWBSZODRWECB-UHFFFAOYSA-N 0.000 claims 1
- UTIKAYGNKRMHTP-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide Chemical compound C1=CC(CNC(CO)C(=O)N)=CC=C1OCC1=CC=CC(F)=C1 UTIKAYGNKRMHTP-UHFFFAOYSA-N 0.000 claims 1
- NEMGRZFTLSKBAP-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-UHFFFAOYSA-N 0.000 claims 1
- FZSPWFMNPPFIJE-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methylsulfanyl]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1SCC1=CC=CC(F)=C1 FZSPWFMNPPFIJE-UHFFFAOYSA-N 0.000 claims 1
- JNSHSOGWMMBDOW-UHFFFAOYSA-N 2-[[4-[(3-methoxyphenyl)methoxy]phenyl]methylamino]propanamide Chemical compound COC1=CC=CC(COC=2C=CC(CNC(C)C(N)=O)=CC=2)=C1 JNSHSOGWMMBDOW-UHFFFAOYSA-N 0.000 claims 1
- KAWCXZXQTSSDOQ-UHFFFAOYSA-N 2-[[4-[(4-fluorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=C(F)C=C1 KAWCXZXQTSSDOQ-UHFFFAOYSA-N 0.000 claims 1
- MBABTXVDELKRJL-UHFFFAOYSA-N 2-[[4-[2-(3-fluorophenyl)ethoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCCC1=CC=CC(F)=C1 MBABTXVDELKRJL-UHFFFAOYSA-N 0.000 claims 1
- FMVVWKBPYPEPAF-UHFFFAOYSA-N 2-[[4-[2-(3-fluorophenyl)ethyl]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1CCC1=CC=CC(F)=C1 FMVVWKBPYPEPAF-UHFFFAOYSA-N 0.000 claims 1
- DABZEFFZGNRXOC-UHFFFAOYSA-N 2-[methyl-[(4-phenylmethoxyphenyl)methyl]amino]propanamide Chemical compound C1=CC(CN(C)C(C)C(N)=O)=CC=C1OCC1=CC=CC=C1 DABZEFFZGNRXOC-UHFFFAOYSA-N 0.000 claims 1
- AROJRYZKACVPEC-UHFFFAOYSA-N 2-phenyl-2-[(4-phenylmethoxyphenyl)methylamino]acetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1 AROJRYZKACVPEC-UHFFFAOYSA-N 0.000 claims 1
- JMIJOQDPXHRPOI-UHFFFAOYSA-N 3-hydroxy-2-[(4-phenylmethoxyphenyl)methylamino]propanamide Chemical compound C1=CC(CNC(CO)C(=O)N)=CC=C1OCC1=CC=CC=C1 JMIJOQDPXHRPOI-UHFFFAOYSA-N 0.000 claims 1
- PPNQCSNKEHUNCF-UHFFFAOYSA-N 3-hydroxy-n-methyl-2-[(4-phenylmethoxyphenyl)methylamino]propanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC=C1 PPNQCSNKEHUNCF-UHFFFAOYSA-N 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- PFZGGJTWPMATOE-UHFFFAOYSA-N n-methyl-3-phenyl-2-[(4-phenylmethoxyphenyl)methylamino]propanamide Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1CNC(C(=O)NC)CC1=CC=CC=C1 PFZGGJTWPMATOE-UHFFFAOYSA-N 0.000 claims 1
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04009532A EP1588704A1 (en) | 2004-04-22 | 2004-04-22 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| PCT/EP2005/004166 WO2005102300A1 (en) | 2004-04-22 | 2005-04-19 | α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS |
| EP05736365A EP1737438B1 (en) | 2004-04-22 | 2005-04-19 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02324B true ME02324B (me) | 2016-06-20 |
Family
ID=34924693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-18A ME02324B (me) | 2004-04-22 | 2005-04-19 | Alfa-aminoamidni derivati djelotvorni u tretmanu sindroma nemirnih nogu |
| MEP-2011-56A ME01219B (me) | 2004-04-22 | 2005-04-19 | Alfa-aminoamid derivati korisni u liječenju bolesti zavisnosti |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-56A ME01219B (me) | 2004-04-22 | 2005-04-19 | Alfa-aminoamid derivati korisni u liječenju bolesti zavisnosti |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8445513B2 (pl) |
| EP (3) | EP1588704A1 (pl) |
| JP (1) | JP5020069B2 (pl) |
| KR (2) | KR101195819B1 (pl) |
| CN (1) | CN1942179B (pl) |
| AT (2) | ATE494890T1 (pl) |
| AU (1) | AU2005235428B2 (pl) |
| BR (2) | BRPI0509976B8 (pl) |
| CA (1) | CA2563674C (pl) |
| CY (2) | CY1108494T1 (pl) |
| DE (2) | DE602005009162D1 (pl) |
| DK (2) | DK1737438T3 (pl) |
| ES (2) | ES2313330T3 (pl) |
| HR (2) | HRP20080593T3 (pl) |
| IL (1) | IL178732A (pl) |
| ME (2) | ME02324B (pl) |
| MX (1) | MXPA06012163A (pl) |
| NO (2) | NO337900B1 (pl) |
| NZ (1) | NZ550664A (pl) |
| PL (2) | PL1900362T3 (pl) |
| PT (2) | PT1737438E (pl) |
| RS (2) | RS50667B (pl) |
| RU (1) | RU2403030C2 (pl) |
| SI (2) | SI1900362T1 (pl) |
| WO (1) | WO2005102300A1 (pl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| SI1423168T1 (sl) | 2001-09-03 | 2006-06-30 | Newron Pharm Spa | Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba |
| EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| ES2339021T3 (es) * | 2003-08-25 | 2010-05-14 | Newron Pharmaceuticals S.P.A. | Derivados de alfa-aminoamida utiles como agentes antiinflamatorios. |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| US20080096965A1 (en) * | 2004-09-10 | 2008-04-24 | Newron Pharmaceuticals S.P.A. | (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators |
| JP2008519811A (ja) * | 2004-11-10 | 2008-06-12 | オリオン コーポレーション | 下肢静止不能症候群の治療 |
| EP1963280B1 (en) | 2005-12-22 | 2015-10-28 | Newron Pharmaceuticals S.p.A. | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| DK2474521T3 (en) * | 2006-06-19 | 2016-10-31 | Newron Pharm Spa | High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| DK2155663T3 (en) | 2007-06-15 | 2018-01-22 | Newron Pharm Spa | SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND / OR CALCIUM CHANNEL MODULATORS |
| KR101593627B1 (ko) | 2007-12-11 | 2016-02-11 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 고순도의 ２［４（３ 또는 ２플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법 |
| CA2707646C (en) * | 2007-12-19 | 2016-09-13 | Newron Pharmaceuticals S.P.A. | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders |
| EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| NZ602648A (en) | 2010-04-27 | 2014-10-31 | Newron Pharm Spa | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers |
| US11278651B2 (en) * | 2018-10-17 | 2022-03-22 | Gambro Lundia Ab | Membrane and device for treating restless leg syndrome |
| CN114667963B (zh) * | 2020-12-24 | 2024-04-26 | 中国科学院脑科学与智能技术卓越创新中心 | 一种非人灵长类动物药物成瘾性评估的装置 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1140748A (en) | 1966-06-23 | 1969-01-22 | Ici Ltd | New carboxylic acid derivatives |
| US4049663A (en) | 1972-06-06 | 1977-09-20 | Allen & Hanburys Limited | Ethylene diamine derivatives |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4935429A (en) * | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
| CA1336169C (en) | 1988-03-01 | 1995-07-04 | Walther Birkmayer | Agent for treatment of parkinson's disease |
| IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| EP0520325A1 (de) * | 1991-06-28 | 1992-12-30 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch |
| GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| ES2211904T3 (es) | 1995-05-26 | 2004-07-16 | Pfizer Inc. | Combinaciones para el tratamiento del parkinsonismo que contienen antagonistas selectivos de nmda. |
| WO1997000511A1 (de) | 1995-06-17 | 1997-01-03 | Baumann Guenter | Scheibenkörper |
| GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| GB9515412D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| DE19701619B4 (de) * | 1997-01-17 | 2007-10-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Pramipexol zur Behandlung des restless legs syndroms |
| GB9727521D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| AU761457B2 (en) | 1998-01-12 | 2003-06-05 | Deborah Wenzel | An additive composition also used as a fuel composition comprising water soluble alcohols |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| WO2001034172A2 (en) * | 1999-11-05 | 2001-05-17 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
| WO2001041763A1 (en) * | 1999-12-10 | 2001-06-14 | University Of Cincinnati | Treatment of addiction disorders |
| US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| EP1406631A4 (en) * | 2001-06-13 | 2005-03-23 | Univ Michigan | DOPAMIN RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREFOR |
| SI1511718T1 (sl) * | 2002-05-29 | 2009-08-31 | Hoffmann La Roche | Derivati n-acilaminobenzena kot selektivni inhibitorji monoaminske oksidaze b |
| EP1515921B1 (en) | 2002-06-24 | 2006-03-08 | Rockwool International A/S | Process and apparatus for controlling mineral wool production using a cascade rotor |
| US6900354B2 (en) * | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
| AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| JP2005060370A (ja) * | 2003-07-25 | 2005-03-10 | Kyowa Hakko Kogyo Co Ltd | 医薬組成物 |
| EP1524267A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Substituted benzylaminoalkylene heterocycles |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
-
2004
- 2004-04-22 EP EP04009532A patent/EP1588704A1/en not_active Withdrawn
-
2005
- 2005-04-19 EP EP07022078A patent/EP1900362B1/en not_active Expired - Lifetime
- 2005-04-19 US US11/578,988 patent/US8445513B2/en not_active Expired - Lifetime
- 2005-04-19 KR KR1020067021748A patent/KR101195819B1/ko not_active Expired - Lifetime
- 2005-04-19 EP EP05736365A patent/EP1737438B1/en not_active Expired - Lifetime
- 2005-04-19 ES ES05736365T patent/ES2313330T3/es not_active Expired - Lifetime
- 2005-04-19 ES ES07022078T patent/ES2357559T3/es not_active Expired - Lifetime
- 2005-04-19 DE DE602005009162T patent/DE602005009162D1/de not_active Expired - Lifetime
- 2005-04-19 SI SI200531224T patent/SI1900362T1/sl unknown
- 2005-04-19 PT PT05736365T patent/PT1737438E/pt unknown
- 2005-04-19 SI SI200530430T patent/SI1737438T1/sl unknown
- 2005-04-19 DK DK05736365T patent/DK1737438T3/da active
- 2005-04-19 RS RSP-2008/0531A patent/RS50667B/sr unknown
- 2005-04-19 JP JP2007508825A patent/JP5020069B2/ja not_active Expired - Lifetime
- 2005-04-19 AT AT07022078T patent/ATE494890T1/de active
- 2005-04-19 AU AU2005235428A patent/AU2005235428B2/en not_active Expired
- 2005-04-19 CN CN2005800118905A patent/CN1942179B/zh not_active Expired - Lifetime
- 2005-04-19 DE DE602005025941T patent/DE602005025941D1/de not_active Expired - Lifetime
- 2005-04-19 RU RU2006137079/15A patent/RU2403030C2/ru active
- 2005-04-19 AT AT05736365T patent/ATE405256T1/de active
- 2005-04-19 KR KR1020127003440A patent/KR101238377B1/ko not_active Expired - Lifetime
- 2005-04-19 ME MEP-2016-18A patent/ME02324B/me unknown
- 2005-04-19 DK DK07022078.5T patent/DK1900362T3/da active
- 2005-04-19 CA CA2563674A patent/CA2563674C/en not_active Expired - Lifetime
- 2005-04-19 WO PCT/EP2005/004166 patent/WO2005102300A1/en not_active Ceased
- 2005-04-19 PL PL07022078T patent/PL1900362T3/pl unknown
- 2005-04-19 PT PT07022078T patent/PT1900362E/pt unknown
- 2005-04-19 NZ NZ550664A patent/NZ550664A/en not_active IP Right Cessation
- 2005-04-19 BR BRPI0509976A patent/BRPI0509976B8/pt not_active IP Right Cessation
- 2005-04-19 PL PL05736365T patent/PL1737438T3/pl unknown
- 2005-04-19 MX MXPA06012163A patent/MXPA06012163A/es active IP Right Grant
- 2005-04-19 BR BR122020004541-8A patent/BR122020004541B1/pt active IP Right Grant
- 2005-04-19 ME MEP-2011-56A patent/ME01219B/me unknown
- 2005-04-19 RS RS20110128A patent/RS51791B/sr unknown
- 2005-04-19 HR HR20080593T patent/HRP20080593T3/xx unknown
-
2006
- 2006-10-19 NO NO20064732A patent/NO337900B1/no unknown
- 2006-10-19 IL IL178732A patent/IL178732A/en active IP Right Grant
-
2008
- 2008-11-10 CY CY20081101279T patent/CY1108494T1/el unknown
-
2011
- 2011-03-04 CY CY20111100255T patent/CY1111656T1/el unknown
- 2011-03-30 HR HR20110230T patent/HRP20110230T1/hr unknown
-
2013
- 2013-03-15 US US13/835,445 patent/US8697738B2/en not_active Expired - Lifetime
-
2015
- 2015-07-27 NO NO20150971A patent/NO338870B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110230T1 (hr) | Derivati alfa-aminoamida korisni u tretmanu poremećaja uzrokovanih ovisnošću | |
| JP2006522800A5 (pl) | ||
| FR2861076B1 (fr) | Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique | |
| HRP20020182B1 (en) | Benzamide formulation with histone deacetylase inhibitor activity | |
| BRPI0413000A (pt) | uso de rotigotina para o tratamento de depressão | |
| EA022459B1 (ru) | Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2 | |
| ITMI20011733A0 (it) | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc | |
| EE200300368A (et) | 4-fluoro-N-(indaan-2-üül)bensamiidi kasutamine jafarmatseutiline preparaat | |
| HRP20161456T1 (hr) | 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamidi visoke čistoće, namijenjenu upotrebi kao medikamenti i farmaceutske formulacije koje ih sadrže | |
| CA2614930A1 (en) | Glutamate aggrecanase inhibitors | |
| EA200501022A1 (ru) | Производные бензоазолилпиперазина с активностью антагониста vr1 | |
| DE60332367D1 (de) | Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel | |
| RU2006126346A (ru) | L-аминоамидные производные, используемые для лечения расстройств нижних мочевыводящих путей | |
| RU2428979C2 (ru) | Новые производные нитрокатехола, обладающие активностью в качестве лигандов селектина | |
| PL342706A1 (en) | Novel forms of (2e)-5-amino-5-methylhex-2-enic n-methyl-n{(1r)-1-(n-methyl-n-[(1r)-1-methylcarbamoyl)-2-phenylethyl]carbamoyl}-2-(2-naphtyl)ethyl) amide salt | |
| SG110069A1 (en) | New process for the industrial synthesis of tetraesters of 5-[bis(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates | |
| TWI441631B (zh) | 有效於治療精神障礙之α－胺基醯胺衍生物 | |
| FR2866334B1 (fr) | Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine | |
| EA200702072A1 (ru) | Фенилсодержащие n-ацильные производные аминов и аминокислот, способ их получения, фармацевтическая композиция и их применение | |
| RU2005125919A (ru) | Альфа-аминоамидные производные, применимые в качестве антимигренозных средств | |
| BR0304194A (pt) | Processo para a sìntese industrial do metil diéster do ácido 5-amino-3-carboximetil-4-ciano-2-tiofeno carboxìlico, e aplicação para a sìntese dos sais bivalentes do ácido ranélico e dos hidratos do mesmo | |
| HRP20120344T1 (hr) | N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije | |
| FR2848851B1 (fr) | Procede d'obtention d'un principe actif presentant des capacites apaisantes, principe actif et compositions obtenues | |
| US20070276046A1 (en) | Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents | |
| SMP200700038B (it) | Derivati dell'acido pentanoico 5-fenile come inibitori delle metalloproteinasi della matrice per il trattamento dell'asma e di altre malattie |